Answers are grounded in this paper and cite their sources.
Examines IRS4's role in PI3K activation in multiple solid tumors, suggesting new treatment targets.
epigenetically. IRS4 fueled cancer dependency through PI3K-Akt activation, and domain analysis revealed the PH and PTB domains, which have a predicted drug pocket, to be dispensable, suggesting degradation-based modalities. These data reveal IRS4 as a target in IRS4-expressing cancers and suggest inhibitory approaches.
No takes yet. Share an insight, caveat, or question.
Banu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: